Cameron Miranda
Vanessa's Law, or the Protecting Canadians from Unsafe Drugs Act, was enacted in 2014 and came into force on December 16, 2019. The law amends the Food and Drugs Act, strengthening the regulation of therapeutic products and improving the reporting of adverse reactions by healthcare institutions. The law is named after Vanessa Young, the daughter of a Member of Parliament from Oakville.
| Characteristics | Values |
|---|---|
| Name of the Law | Protecting Canadians from Unsafe Drugs Act (Vanessa's Law) |
| Year of Enactment | 2014 |
| Year of Implementation | 2019 |
| Purpose | To improve patient safety by strengthening the regulation of therapeutic products and improving the reporting of adverse reactions by healthcare institutions |
| Powers Conferred | Ability to order a recall of products, require label changes, impose higher fines and penalties for non-compliance, compel persons to provide information, and disclose confidential business information |
| Products Covered | Therapeutic products including prescription and over-the-counter drugs, vaccines, gene therapies, cells, tissues, organs, and medical devices |
| Regulatory Bodies | Health Canada, Minister of Health |
| Reporting Requirements | Mandatory reporting of serious adverse drug reactions (ADRs) and medical device incidents (MDIs) within 30 days |
| Impact | Increased patient safety, improved detection of health product safety issues, and stronger knowledge leading to safer products |
Explore related products
What You'll Learn
Mandatory reporting of serious adverse drug reactions (ADRs) and medical device incidents (MDIs)
Vanessa's Law, or the Protecting Canadians from Unsafe Drugs Act, was enacted in 2014 and came into effect on December 16, 2019. The law amends the Food and Drugs Act to strengthen the regulation of therapeutic products and improve the reporting of adverse reactions by healthcare institutions.
Under Vanessa's Law, hospitals are required to report serious adverse drug reactions (ADRs) and medical device incidents (MDIs) to Health Canada within thirty days of the event being documented. This mandatory reporting is intended to improve the quality and quantity of reports, thereby optimising the detection of health product safety issues. ADRs and MDIs are often only detected after market approval, so increasing the number of reports helps Health Canada to identify issues and act quickly.
The law defines a hospital as a facility that is licensed, approved, or designated as a hospital by a province or territory to provide care or treatment for diseases or illnesses. Outpatient clinics are also subject to the regulations if they are legally part of the hospital, even if they are physically separate.
The mandatory reporting requirements also apply to certain healthcare institutions, which must report serious adverse drug reactions and medical device incidents to the Minister of Health. Healthcare institutions, such as hospitals, are in a unique position to identify and report serious adverse reactions, as most drugs are prescribed and used by patients outside of these institutions.
The Minister of Health has the authority to gather more information about a product by compelling persons or therapeutic product authorisation holders to provide information or conduct new tests or studies. The Minister may also disclose confidential business information about a therapeutic product if they believe it is necessary to determine whether it presents a serious health risk.
The Law That Criminalizes Feeding the Homeless
You may want to see also
Explore related products
Amendments to the Food and Drugs Act
The Protecting Canadians from Unsafe Drugs Act, or Vanessa's Law, introduces amendments to the Food and Drugs Act that will improve Health Canada's ability to collect post-market safety information and take appropriate action when a serious health risk is identified. These amendments will improve the protection of patient health and safety and increase consumer confidence in therapeutic products on the market.
The new legislation will update the laws that apply to drugs and medical devices to increase patient safety in key areas of concern. It will enable the government to require strong surveillance, including mandatory adverse drug reaction reporting by healthcare institutions. It will also impose tough new penalties for unsafe products, including jail time and new fines of up to $5 million per day instead of the current $5,000. The courts will also have the discretion to impose even stronger fines if violations were caused intentionally.
The Minister of Health will now have the authority to gather more information about a product by compelling persons to provide information for the purpose of assessing serious risks to health or by requiring a therapeutic product authorisation holder to compile information, conduct new tests or studies, or monitor experience. The Minister of Health may also direct a therapeutic product authorisation holder to assess the benefits, harms, and uncertainties of a product.
The Minister of Health will also have the authority to disclose confidential business information about a therapeutic product if they believe it is necessary to determine whether a therapeutic product presents a serious risk of injury to human health. Additionally, the Minister may now disclose confidential business information about a therapeutic product to a government, a person from whom the Minister seeks advice, or a person who carries out functions relating to the protection or promotion of human health or the safety of the public.
As of June 22, 2023, the powers conferred by the Protecting Canadians from Unsafe Drugs Act (Vanessa's Law) apply to natural health products (NHPs). This is because the definition of "therapeutic product" has been revised in the Food and Drugs Act to include natural health products.
Foreign Law: Can US Courts Apply It?
You may want to see also
Explore related products
Increased powers for Health Canada
Vanessa's Law, or the Protecting Canadians from Unsafe Drugs Act, was enacted in 2014 and came into effect on December 16, 2019. The law amends the Food and Drugs Act, strengthening the regulation of therapeutic products and improving the reporting of adverse reactions by healthcare institutions. The law is named after Vanessa Young, the daughter of a Member of Parliament from Oakville.
Under Vanessa's Law, Health Canada has been granted several new powers to protect Canadians from unsafe products. Firstly, hospitals are now required to report serious adverse drug reactions (ADRs) and medical device incidents (MDIs) to Health Canada within thirty days of the event being documented. This mandatory reporting is intended to improve the quality and quantity of reports, enabling Health Canada to optimize the detection of health product safety issues.
Secondly, Health Canada now has the authority to order recalls of therapeutic products, including natural health products, that present a serious or imminent risk of injury to human health. They can also require label changes or package modifications to prevent serious injury to health.
Thirdly, Health Canada can impose higher fines and penalties for non-compliance with safety regulations. These penalties can include jail time and fines of up to $5 million per day, a significant increase from the previous $5,000 daily fine.
Additionally, the Minister of Health has been granted enhanced powers under Vanessa's Law. The Minister can now compel persons or therapeutic product authorization holders to provide information or conduct further testing to assess serious health risks. The Minister also has the authority to disclose confidential business information about a therapeutic product if they believe it is necessary to determine whether it presents a serious risk to human health.
Overall, Vanessa's Law strengthens Health Canada's ability to regulate therapeutic products, improve patient safety, and take appropriate action when serious health risks are identified.
Common Law: Private Citizen Suits Explained
You may want to see also
Explore related products
Strengthened safety oversight of therapeutic products
Vanessa's Law, or the Protecting Canadians from Unsafe Drugs Act, was enacted in 2014 and came into effect on December 16, 2019. The law amends the Food and Drugs Act to strengthen safety oversight of therapeutic products, which include prescription and over-the-counter drugs, vaccines, gene therapies, cells, tissues, organs, and medical devices.
The law gives the Minister of Health greater authority to gather information about therapeutic products and assess their risks. The Minister can compel persons or therapeutic product authorization holders to provide information or conduct further tests and studies. Additionally, the Minister can disclose confidential business information about a therapeutic product if it may present a serious risk to human health.
The law also introduces mandatory reporting requirements for hospitals, which must report serious adverse drug reactions (ADRs) and medical device incidents (MDIs) to Health Canada within thirty days of the event being documented. This reporting helps to strengthen Health Canada's knowledge base, enabling them to identify safety issues and take appropriate action to protect public health.
To further strengthen safety oversight, Vanessa's Law empowers Health Canada to order recalls of unsafe products, impose tougher penalties for non-compliance, and compel drug companies to revise labels or conduct further testing to address health risks. These measures aim to increase patient safety and improve transparency in the oversight of therapeutic products.
As of June 22, 2023, the scope of Vanessa's Law was expanded to include natural health products (NHPs) under the definition of "therapeutic product", ensuring that all therapeutic products are subject to stringent safety oversight.
Martial Law in Philippines: Could It Return?
You may want to see also
Explore related products
Improved reporting of serious adverse reactions by healthcare institutions
Vanessa's Law, or the Protecting Canadians from Unsafe Drugs Act, was enacted in 2014 and came into effect on December 16, 2019. The law amends the Food and Drugs Act, strengthening the regulation of therapeutic products and improving the reporting of adverse reactions by healthcare institutions.
Under Vanessa's Law, certain healthcare institutions, such as hospitals, are required to report serious adverse drug reactions (ADRs) and medical device incidents (MDIs) to Health Canada within thirty days of the event being documented. This mandatory reporting is intended to improve the quality and quantity of reports, thereby optimising the detection of health product safety issues.
The law outlines specific reporting processes for hospitals to meet these mandatory reporting requirements. Healthcare leadership and providers are encouraged to promote and support the reporting of serious ADRs and MDIs. Once a report is submitted, Health Canada shares and analyses the information, providing feedback to those who reported it and sharing learnings and improvements.
The Minister of Health has been granted additional powers under Vanessa's Law. They can now compel persons or therapeutic product authorisation holders to provide information for assessing serious health risks. The Minister can also disclose confidential business information if they believe a therapeutic product may present a serious risk to human health.
Overall, Vanessa's Law aims to improve patient safety in Canada by strengthening the regulation of therapeutic products and enhancing the reporting of adverse reactions by healthcare institutions. These measures are designed to improve Health Canada's ability to collect safety information and take appropriate action when serious health risks are identified.
California Senators: Proposing Federal Laws?
You may want to see also
Frequently asked questions
Vanessa's Law is the Protecting Canadians from Unsafe Drugs Act, which amends the Food and Drugs Act to improve safety and strengthen the regulation of therapeutic products.
Vanessa's Law empowers Health Canada to order recalls, impose tougher penalties for unsafe products, and compel drug companies to review labels or do further testing on products. It also requires hospitals to report serious adverse drug reactions (ADRs) and medical device incidents (MDIs) to Health Canada within thirty days of the event being documented.
The purpose of Vanessa's Law is to increase patient safety in Canada by improving Health Canada's ability to collect safety information on marketed therapeutic products.
Vanessa's Law was enacted in 2014 and the mandatory reporting requirements came into effect on December 16, 2019.
